Please ensure Javascript is enabled for purposes of website accessibility

Why MiMedx Group Inc. Is Sinking Today

By Brian Feroldi - Oct 23, 2017 at 4:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares tumble on little news -- are short-sellers behind the move?

What happened

Shares of MiMedx Group (MDXG 2.88%), a biopharmaceutical company focused on regenerative medicine, fell 10% as of 3:45 p.m. EDT on Monday. However, there doesn't appear to be any company-specific news that can help to explain the sell-off.

So what

MiMedx Group has been targeted by short-sellers over the last month, so today's volatility could simply be attributable to more activity on this front. That seems likely since the number of shares that have been sold short has jumped over the past two months:

Date Short interest
8/15/2017 22.0 million
8/31/2017 23.3 million
9/15/2017 25.6 million
9/29/2017 29.5 million

Data source: Nasdaq.

For what it is worth, MiMedx Group's management team has done its best to combat the attack by posting a series of responses on its investor relations page.

Chart with arrow trending downward, with a frustrated businessman in foreground

Image source: Getty Images.

Another tactic that management had used to reassure investors was to preannounce third-quarter results. The company stated that it expects third-quarter revenue to come in around $84.6 million, which is well ahead of its guidance range of $79 million to $80 million. That represents growth of 31% year over year, which is very strong. The company also stated that accounts-receivable days sales outstanding (DSO) -- a common calculation that is used to estimate a company's average collection period -- fell to the mid-60s.

If all of that wasn't enough, MiMedx's board of directors also recently authorized an additional $10 million in share repurchases.

Commenting on the repurchase activity, CEO Pete Petit said:

The recent deceptive and contrived attacks on our stock have caused the MiMedx shares to become very undervalued in my opinion. I believe it is a very prudent use of our capital to acquire our shares at this point, and our high growth profile in both revenues and profits should produce an extremely anti-dilutive result from our stock repurchases.

In spite of these aggressive responses, the high number of shares sold short is likely to keep the share price volatile for the foreseeable future.

Now what

Short-term price action aside, MiMedx's investors should do their best to remain heads-down and focus on the long-term potential of the business. A brief look back at MiMedx's growth over the last few years shows that the company has stumbled upon a winning business model:

MDXG revenue, net income, and share-price growth (past five years)

MDXG Revenue (Annual) data by YCharts.

MiMedx will officially announce its third-quarter earnings results on Friday at 10:30 a.m. EDT. Bulls and bears alike would be advised to listen in for clues about what's next for this business.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MiMedx Group, Inc. Stock Quote
MiMedx Group, Inc.
MDXG
$3.57 (2.88%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.